Targeting ubiquitin in cancers

European Journal of Cancer

Volumn 42, Issue 18, 2006, Pages 3095-3102

  Dikic, Ivan ^a   Crosetto, Nicola ^a   Calatroni, Silvia ^b   Bernasconi, Paolo ^b  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Bortezomib; Leukaemia; Lymphoma; Multiple myeloma; Ub system targeted drugs; Ubiquitin

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; ANTINEOPLASTIC AGENT; BORTEZOMIB; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GELDANAMYCIN; LENALIDOMIDE; MELPHALAN; NPI 0052; NUTLIN 3; PREDNISONE; SALINOSPORIN A; SHEPHERDIN; THALIDOMIDE; UBIQUITIN; VINCRISTINE;

ARTICLE; CANCER; CARCINOGENESIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; HEMATOLOGIC MALIGNANCY; HUMAN; LOW DRUG DOSE; LYMPHOMA; MANTLE CELL LYMPHOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION; TUMOR CELL;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CELL COMMUNICATION; CELL CYCLE; GENE THERAPY; HEAT-SHOCK PROTEINS; HUMANS; LACTONES; NEOPLASMS; PYRAZINES; PYRROLES; UBIQUITIN;

EID: 33845203166     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.05.041     Document Type: Article

References (57)

1. Hershko A., and Ciechanover A. The ubiquitin system. Annu Rev Biochem 67 (1998) 425-479
2. Haglund K., and Dikic I. Ubiquitylation and cell signaling. EMBO J 24 19 (2005) 3353-3359
3. Pickart C.M. Mechanisms underlying ubiquitination. Annu Rev Biochem 70 (2001) 503-533
4. Ciechanover A., Orian A., and Schwartz L. Ubiquitin-mediated proteolysis: biological regulation via destruction. BioEssays 22 (2000) 442-451
5. Elasser S., and Finley D. Delivery of ubiquitinated substrates to protein-unfolding machines. Nat Cell Biol 7 (2005) 742-749
6. Hicke L. Protein regulation by monoubiquitin. Nat Rev Mol Cell Biol 2 3 (2001) 195-201
7. Hicke L., Schubert H.L., and Hill C.P. Ubiquitin-binding domains. Nat Rev Mol Cell Biol 6 8 (2005) 610-621
8. Di Fiore P.P., Polo S., and Hofmann K. When ubiquitin meets ubiquitin receptors: a signalling connection. Nat Rev Mol Cell Biol 4 6 (2003) 491-497
9. Bienko M., Green C.M., Crosetto N., et al. Ubiquitin-binding domains in Y-family polymerases regulate translesion synthesis. Science 310 5755 (2005) 1821-1824
10. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 1 (2000) 57-70
11. Burger A.M., and Seth A.K. The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications. Eur J Cancer 40 (2004) 2217-2229
12. Mani A., and Gelmann E.P. The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 23 (2005) 4776-4789
13. Hoeller D., Hecker C.M., and Dikic I. Ubiquitin and Ubl proteins in cancer pathogenesis. Nat Rev Cancer 6 10 (2006) 776-788
14. Wasch R., and Engelbert D. Anaphase-promoting complex-dependent proteolysis of cell cycle regulators and genomic instability of cancer cells. Oncogene 24 1 (2005) 1-10
15. Guardavaccaro D., and Pagano M. Oncogenic aberrations of cullin-dependent ubiquitin ligases. Oncogene 23 11 (2004) 2037-2049
16. Keiichi I. Nakayama, Keiko Nakayama. Ubiquitin ligases: cell-cycle control and cancer. Nature Reviews Cancer 6, 369-381.
17. Nalepa G., Rolfe M., and Harper J.W. Drug discovery in the ubiquitin-proteasome system. Nat Rev Drug Discov 5 7 (2006) 596-613
18. Haglund K., Di Fiore P.P., and Dikic I. Distinct monoubiquitin signals in receptor endocytosis. Trends Biochem Sci 28 11 (2003) 598-603
19. Peschard P., and Park M. Escape from Cbl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases. Cancer Cell 3 6 (2003) 519-523
20. Crosetto N., Tikkanen R., and Dikic I. Oncogenic breakdowns in endocytic adaptor proteins. FEBS Lett 579 15 (2005) 3231-3238
21. Dierlamm J et al. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood 93:3601-3609.
22. Akagi T et al. A novel gene, MALT1 at 18q21, is involved in t(11;18) (q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue. Oncogene 18: 5785-5794.
23. Morgan JA et al. Breakpoints of the t(1118)(q21;q21) in mucosa-associated lymphoid tissue (MALT) lymphoma lie within or near the previously undescribed gene MALT1 in chromosome 18. Cancer Res 59:6205-6213.
24. Hu S., et al. cIAP2 is a ubiquitin protein ligase for BCL10 and is dysregulated in mucosa-associated lymphoid tissue lymphomas. J Clin Invest 116 1 (2006) 174-181
25. Jackson G., Einsele H., Moreau P., and San Migule J. Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies. Cancer Treat Rev 31 (2005) 591-602
26. Lightcap E.S., McCormack T.A., Pien C.S., et al. Proteasome inhibition measurements: clinical application. Clin Chem 45 (2000) 673-683
27. Papandreou C., Daliani K.K., Nix D., et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22 (2004) 2108-2121
28. Richardson P.G., Barbogie B., Berenson J., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348 (2003) 2609-2617
29. Richardson P.G., Barbogie B., Berenson J., et al. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma. Cancer 106 (2006) 1316-1319
30. Jagannath S., Barlogie B., Berenson J., et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127 (2004) 165-172
31. Richardson P.G., Sonneveld P., Schuster M.W., et al. Bortezomib or high-dose Dexamethasone for relapsed multiple myeloma. New Engl J Med 352 (2005) 2487-2498
32. Kroppf M., Bisping G., Liebisch P., et al. Bortezomib in combination with high-dose dexamethasone and continuos low-dose oral cyclophosphamide for relapsed multiple myeloma. Blood 106 (2005) 716a
33. Palumbo A., Ambrosini M.T., Pregno P., et al. Velcade plus melphalan, prednisone and thalidomide (V-MPT) for advanced multiple myeloma. Blood 106 (2005) 717a
34. Chanan-Khan A, Chanan-Khan AA, Miller KC, et al. Bortezomib (Velcade V) in combination with pegylated liposomal doxorubicin (D) and Thalidomide (T) yield high response rate in patients (pts) with relapsed or refractory multiple myeloma (MM). Haematologica 2005; 90 (suppl. 2), abs 633.
35. Richardson P.G., Barbogie B., Berenson J., et al. Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood 106 (2005) 2977-2981
36. Jagannath S., Durie B.G., Wolf J., et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Brit J Haematol 129 (2005) 776-783
37. Harousseau J., Attal M., Coiteux V., et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: Preliminary Results of an IFM Phase II Study. J Clin Oncol 23 suppl 16 (2005) 589s
38. Popat R., Oakervee H.E., Curry N., et al. Reduced dose PAD combination therapy (PS341/Bortezomib, adriamycin and dexamethasone) for previously untreated patients with multiple myeloma. Blood 106 (2005) 717a
39. Wang M., Delasalle K., Giralt S., et al. Rapid control of previously untreated multiple myeloma with Bortezoomib-Thalidomide-Dexamethasone followed by early intensive therapy. Blood 106 (2005) 231a
40. Mateos MV, Hernandez JM, Hernandez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase I/II study. Blood 2006 [pre-published online June 13].
41. Goy A., Younes A., McLaughlin P., et al. Phase II study of proteasome inhibitor in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23 (2005) 567-575
42. Dunleavy K., Janik J., Gea-Banacloche J., et al. Phase I/II study of bortezomib alone and bortezomib with dose-adjusted EPOCH chemotherapy in relapsed or refractory aggressive B-cell lymphoma. Blood 104 (2004) 389a
43. Machela V.R., Mitchell S.S., Manam R.R., et al. Structure-activity relationship studies of a salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor. J Med Chem 48 (2005) 3684-3687
44. Ruiz S., Krupnik Y., Keating M., et al. The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukaemia. Mol Cancer Ther 5 (2006) 1836-1843
45. Chauhan D., Catley l., Li G., et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib. Cancer Cell 8 (2005) 407-419
46. Vousden K.H., and Prives C. P53 and prognosis: new insights and further complexity. Cell 120 (2005) 7-10
47. Oren M. Decision making by p53: life, death and cancer. Cell Death Differ 10 (2003) 431-442
48. Secchiero P., Barbarotto E., Tribelli M., et al. Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukaemia (B-CLL). Blood 107 (2006) 4122-4129
49. Coll-Mulet L., Iglesias-Serret D., Santidrian A.F., et al. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukaemia cells. Blood 107 (2006) 4109-4114
50. Kojima K., Konopleva M., McQueen T., et al. MDM2 inhibitor nutlin3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome ATM-mediated resistance to fludarabine in chronic lymphocytic leukaemia. Blood 108 (2006) 993-1000
51. Kojima K., Konopleva M., Samudio I.J., et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukaemia therapy. Blood 106 (2005) 3150-3159
52. Goetz M.P., Toft D.O., Ames M.M., and Erlichman C. The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol 14 (2003) 1169-1176
53. Sharp S., and Workman P. Inhibitors of the Hsp90 molecular chaperone: current status. Adv Cancer Res 95 (2006) 323-348
54. Mesa R.A., Logering D., Powell H.L., et al. Heat shock protein 90 inhibition sensitises acute myelogenous leukaemia cells to cytarabine. Blood 106 (2005) 318-327
55. Thomas X., Campos L., Le Q.-H., and Guyotat D. Heat shock proteins and acute leukemias. Hematology 10 (2005) 225-235
56. Blagosklonny M.V., Fojo T., Bhalla K.N., et al. The Hsp90 inhibtor geldanamycin selectively sensitises Bcr-Abl expressing leukaemia cells to cytotoxic chemotherapy. Leukemia 15 (2001) 1537-1543
57. Gyurkocza B., Plescia J., Raskett C.M., et al. Antileukemic activity of Shepherdin and molecular diversity of hsp90 inhibitors. J Natl Cancer Inst 98 (2006) 1068-1077